lncRNA SLC9A3-AS1 Promotes Oncogenesis of NSCLC via Sponging microRNA-760 and May Serve as a Prognosis Predictor of NSCLC Patients

Huang, Xiaojuan; Huang, Mingyue; Chen, Mingxu; Chen, X

doi:10.2147/cmar.s352308

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In lung carcinomas, differential expression of lncRNAs has been observed depending on the cancer type. Representative cases are SLC9A3-AS1, reported upregulated; LINC01554 and GABPB1 reported downregulated in NSCLC tissues [166][167][168], while RBPMS-AS1 expression was found to be diminished in lung adenocarcinoma [169]. Other studies have shown the reduced expression of LINC00294 in colorectal carcinoma tissues [170], while SLFNL1-AS1, KCNQ1OT1, NEAT1, XIST, AC016876.2, AC026362.1 were found to be downregulated in colon cancer cell lines [171].…”

Section: Discussionmentioning

confidence: 96%

miRNAs as Interconnectors between Obesity and Cancer

González-Sánchez,

Granados-López,

López-Hernández

et al. 2024

ncRNA

View full text Add to dashboard Cite

Obesity and cancer are a concern of global interest. It is proven that obesity may trigger the development or progression of some types of cancer; however, the connection by non-coding RNAs has not been totally explored. In the present review, we discuss miRNAs and lncRNAs dysregulation involved in obesity and some cancers, shedding light on how these conditions may exacerbate one another through the dysregulation of ncRNAs. lncRNAs have been reported as regulating microRNAs. An in silico investigation of lncRNA and miRNA interplay is presented. Our investigation revealed 44 upregulated and 49 downregulated lncRNAs in obesity and cancer, respectively. miR-375, miR-494-3p, miR-1908, and miR-196 were found interacting with 1, 4, 4 and 4 lncRNAs, respectively, which are involved in PPARγ cell signaling regulation. Additionally, miR-130 was found to be downregulated in obesity and reported as modulating 5 lncRNAs controlling PPARγ cell signaling. Similarly, miR-128-3p and miR-143 were found to be downregulated in obesity and cancer, interacting with 5 and 4 lncRNAs, respectively, associated with MAPK cell signaling modulation. The delicate balance between miRNA and lncRNA expression emerges as a critical determinant in the development of obesity-associated cancers, presenting these molecules as promising biomarkers. However, additional and deeper studies are needed to reach solid conclusions about obesity and cancer connection by ncRNAs.

show abstract

Section: Discussionmentioning

confidence: 96%

miRNAs as Interconnectors between Obesity and Cancer

González-Sánchez,

Granados-López,

López-Hernández

et al. 2024

ncRNA

View full text Add to dashboard Cite

show abstract

“…LINC01748 plays a carcinogenic role in non−small cell lung cancer cell lines through the regulation of the microRNA−520a−5p/HMGA1 axis ( 24 ). SLC9A3-AS1 is upregulated in NSCLC, and the SLC9A3-AS1 gene knockout hinders NSCLC progression by targeting miR-760, implying that it may have a role as a new biomarker and therapeutic target of NSCLC ( 25 ). Due to the important role of lncRNAs in cancers, the implications of lncRNAs for the prognoses of LUAD patients have been widely studied ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Cuproptosis-related lncRNA signatures: Predicting prognosis and evaluating the tumor immune microenvironment in lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

BackgroundCuproptosis, a unique kind of cell death, has implications for cancer therapy, particularly lung adenocarcinoma (LUAD). Long non-coding RNAs (lncRNAs) have been demonstrated to influence cancer cell activity by binding to a wide variety of targets, including DNA, RNA, and proteins.MethodsCuproptosis-related lncRNAs (CRlncRNAs) were utilized to build a risk model that classified patients into high-and low-risk groups. Based on the CRlncRNAs in the model, Consensus clustering analysis was used to classify LUAD patients into different subtypes. Next, we explored the differences in overall survival (OS), the tumor immune microenvironment (TIME), and the mutation landscape between different risk groups and molecular subtypes. Finally, the functions of LINC00592 were verified through in vitro experiments.ResultsPatients in various risk categories and molecular subtypes showed statistically significant variations in terms of OS, immune cell infiltration, pathway activity, and mutation patterns. Cell experiments revealed that LINC00592 knockdown significantly reduced LUAD cell proliferation, invasion, and migration ability.ConclusionThe development of a trustworthy prediction model based on CRlncRNAs may significantly aid in the assessment of patient prognosis, molecular features, and therapeutic modalities and may eventually be used in clinical applications.

show abstract